MADRID, June 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported data highlighting ...
Cytosine and adenosine base editors (CBEs and ABEs) are integral to molecular breeding, enable precise modification of single-nucleotide polymorphisms (SNPs) in plants, which are crucial for agronomic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results